Biology of Blood and Marrow Transplantation · 2010 · 10 citations · 0 references
MedicineOncologyPharmacoeconomicsCost-effectiveness AnalysisOutcomes ResearchStem Cell TransplantationAutologous Stem Cell TransplantationCellular TherapyChemotherapy In Hematologic MalignanciesHematologic Malignancy TherapyStem Cell MobilizationAutologous Hematopoietic Stem Cell MobilizationComparative Cost-effectivenessCost-effectivenessCyclophosphamide MobilizationG-csf TherapyGranulocyte Colony-stimulating Factor MobilizationGranulocyte-macrophage Colony-stimulating Factor MobilizationPeripheral Blood Stem Cells
Chemomobilization of autologous peripheral blood stem cells (PBSCs) is costly and requires substantial resource allocations. This burden has considerable effects on patients (pts), providers and payers. We performed a retrospective study to evaluate the difference in costs and effectiveness of first-line mobilization of autologous PBSCs with cyclophosphamide (CY; 1.5-4 gm/m2)+G-CSF (n=34) versus plerixafor+G-CSF (n=8) in pts with non-Hodgkin's lymphoma (NHL) between 6/2006 and 8/2009.